ASKA Pharmaceutical Holdings (4886) · InitiativeRestated
Stable Supply of Tiratricol and Thyroid Disease Awareness Activities
First written in FY2022. 2 of 3 entries say "Restated". Latest entry: FY2024.
3entries
3years
0from disclosures
How it moved
Same theme, other companies
Stable Supply of Tiratricol and Thyroid Disease Awareness ActivitiesA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2024RestatedAnnual report
「国内シェアが9割を超えるチラーヂンは医療現場において欠かすことのできない薬剤であり、安定供給体制を堅持するとともに、甲状腺疾患治療のリーディングカンパニーとして引き続き甲状腺疾患の啓発活動等に取り組んでまいります。」
チラーヂンの安定供給と甲状腺疾患啓発を継続する方針を再掲している。 - FY2023RestatedAnnual report
「国内シェアが9割を超えるチラーヂンは医療現場において欠かすことのできない薬剤であり、安定供給体制を堅持するとともに、甲状腺疾患治療のリーディングカンパニーとして引き続き甲状腺疾患の啓発活動等に取り組んでまいります。」
チラーヂンの安定供給と甲状腺疾患啓発を継続する方針を再掲している。 - FY2022First statedAnnual report
「Tiratricol, which has been on the market for 100 years and has a domestic market share of more than 90%, is indispensable in medical practice. We will maintain a stable supply system and continue awareness activities for thyroid diseases as a leading company in thyroid disease treatment.」
For Tiratricol, which has been marketed for 100 years and holds more than 90% of the domestic market, the company combines maintaining stable supply with thyroid disease awareness activities.